|
1.Hosseinzadeh, H. and S. Parvardeh. Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine, 2004. 11(1): 56-64.
2.Hosseinzadeh, H. and S. Parvardeh. Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine, 2004. 11(1): 56-64.
3.Nagi, Mahmoud N,Alam, Khurshid,Badary, Osama A,Al‐Shabanah, Othman A,Al‐Sawaf, Hussein A, Al‐Bekairi and Abdullah M. Thymoquinone protects against carbon tetrachloride hetatotoxicity in mice via an antioxidant mechanism. IUBMB Life, 1999. 47(1): 153-159.
4.Al-Shabanah, OA,Badary, OA,Nagi, MN,Al-Gharably, NM,Al-Rikabi, AC and Al-Bekairi, AM . Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. Journal of experimental & clinical cancer research: CR, 1998. 17(2): 193-198.
5.Badary, Osama A,Nagi, Mahmoud N,Al-Shabanah, Othman A,Al-Sawaf, Hussain A,Al-Sohaibani, Mohammed O and Al-Bekairi, Abdullah M. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Canadian Journal of Physiology and Pharmacology, 1997. 75(12): 1356-1361.
6.Yi, Tingfang,Cho, Sung-Gook,Yi, Zhengfang,Pang, Xiufeng,Rodriguez, Melissa,Wang, Ying,Sethi, Gautam,Aggarwal, Bharat B and Liu, Mingyao. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Molecular Cancer Therapeutics, 2008, 7(7): 1789-1796.
7.Fisher, A. and M. Davis, Calcium-PTH-vitamin D axis in older patients with hip fracture. Osteoporosis International, 2007. 18(5): 693-695.
8.Brickman, Arnolds,Coburn, Jackw,Massry, Shaulg and Norman, Anthonyw. 1, 25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Annals of Internal Medicine, 1974. 80(2): 161-167.
9.Eckardt, K. Pathophysiology of renal anemia. Clinical Nephrology, 2000. 53(1 Suppl): S2-8.
10.Weir, M.R. and V.J. Dzau. The renin-angiotensin-aldosterone system: a specific target for hypertension management. American Journal of Hypertension, 1999. 12(S9): 205S-213S.
11.Michell, A., E. Debnam, and R. Unwin.Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. Annu. Rev. Physiol., 2008. 70: 379-403.
12.Knight, S.F. and J.D. Imig. Obesity, insulin resistance, and renal function. Microcirculation, 2007. 14(4-5): 349-362.
13.Jorgensen, P.. Structure, function and regulation of Na, K-ATPase in the kidney. Kidney Int, 1986. 29(1): 10-20.
14.Ruggenenti, Piero,Gaspari, Flavio,Perna, Annalisa and Remuzzi, Giuseppe. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. Bmj, 1998. 316(7130): 504-509.
15.Chow, W.-H., L.M. Dong, and S.S. Devesa,. Epidemiology and risk factors for kidney cancer. Nature Reviews Urology, 2010. 7(5): 245-257.
16.Lopez-Beltran, Antonio,Scarpelli, Marina and Montironi, Rodolfo. 2004 WHO classification of the renal tumors of the adults. European Urology, 2006. 49(5): 798-805.
17.Luciani, L.G., R. Cestari, and C. Tallarigo.Incidental renal cell carcinoma—age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology, 2000. 56(1): 58-62.
18.Nese, Nalan,Paner, Gladell P,Mallin, Katherine,Ritchey, Jamie,Stewart, AndrewAnd Amin, Mahul B. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47 909 cases using the National Cancer Data Base. Annals of Diagnostic Pathology, 2009. 13(1): 1-8.
19.Mickisch, G.H.. Multimodality treatment of metastatic renal cell
carcinoma. Expert Rev Anticancer Ther, 2002. 2(6): 681-685
20.Mimi, C Yu,Mack, Thomas M,Hanisch, Rosemarie,Cicioni, Carlaand Henderson, Brian E. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. Journal of The National Cancer Institute, 1986. 77(2): 351-356.
21.Chow, Wong-Ho,Gridley, Gloria,Fraumeni Jr, Joseph FAnd Järvholm, Bengt. Obesity, hypertension, and the risk of kidney cancer in men. New England Journal of Medicine, 2000. 343(18): 1305-1311.
22.Smith, Allan H,Hopenhayn-Rich, Claudia,Bates, Michael N,Goeden, Helen M,Hertz-Picciotto, Irva,Duggan, Heather M,Wood, Rose,Kosnett, Michael Jand Smith, Martyn T. Cancer risks from arsenic in drinking water. Environmental Health Perspectives, 1992. 97: 259.
23.Stengel, B.. Chronic kidney disease and cancer: a troubling connection. Journal of Nephrology, 2010. 23(3): 253.
24.Fairley, K.F. and D.F. Birch. Hematuria: a simple method for identifying glomerular bleeding.Kidney International, 1982. 21(1): 105-108.
25.Escudier, B,Eisen, T,Porta, C,Patard, JJ,Khoo, V,Algaba, F,Mulders, P,Kataja, V and ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012. 23(suppl 7): vii65-vii71.
26.Sheth S, Scatarige JC, Horton KM et-al. Current concepts in the
diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics. 2001;21 Spec No : S237-54.
27.Mickisch, Gerald, Carballido, Joaquin, Hellsten, Sverker, Schulze, Harald and Mensink, Han. Guidelines on renal cell cancer. European urology, 2001. 40(3): 252-255.
28.Rini, B.I., S.C. Campbell, and B. Escudier. Renal cell carcinoma. The
Lancet, 2009. 373(9669): 1119-1132.
29.Atkins, M.B., M. Regan, and D. McDermott. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clinical Cancer Research, 2004. 10(18): 6342S-6346S.
30.Davies, K.J.. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life, 1999. 48(1): 41-47.
31.Dieckmann, K.P. and N. Skakkebaek. Carcinoma in situ of the testis: review of biological and clinical features. International Journal of Cancer, 1999. 83(6): 815-822.
32.Nicolson, G.L.. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer and Metastasis Reviews, 1988. 7(2): 143-188.
33. Bernards, R. and R.A. Weinberg.A progression puzzle. Nature,
2002. 418(6900): 823.
34.Hood, J.D. and D.A. Cheresh. Role of integrins in cell invasion and migration. Nature Reviews Cancer, 2002. 2(2): 91-100.
35.Friedl, P. and K. Wolf. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer, 2003. 3(5): 362-374.
36.Folkman, J.. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1995. 1(1): 27-30.
37.Stetler-Stevenson, W.G., S. Aznavoorian and L.A. Liotta. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annual Review of Cell Biology, 1993. 9(1): 541-573.
38.He, Yu,Chen, Zhi-yu,Zhu, Jin,Xiong, Yan,Li, Kun,Dong, Jia-hong and Li, Xiaowu. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clinical Cancer Research, 2007, 13(11): 3115-3124.
39.Haas T L, Davis S J and Madri J A. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. Journal of Biological Chemistry, 1998, 273(6): 3604-3610.
40.Patel, P.H., R.S. Chaganti, and R.J. Motzer. Targeted therapy for
metastatic renal cell carcinoma. Br J Cancer, 2006. 94(5): 614-9.
41.Yang J, Weinberg R A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis[J]. Developmental Cell, 2008, 14(6): 818-829.
42.Huber, Margit A., Norbert Kraut, and Hartmut Beug. "Molecular requirements for epithelial–mesenchymal transition during tumor progression. Current Opinion In Cell Biology,2005,17(5): 548-558.
43.Wendt M K, Allington T M, Schiemann W P. Mechanisms of the epithelial-mesenchymal transition by TGF-β. Future Oncology, 2009, 5(8): 1145-1168.
44.Cano, Amparo,Pérez-Moreno, Mirna A,Rodrigo, Isabel,Locascio, Annamaria,Blanco, María J,del Barrio, Marta G,Portillo, Francisco and Nieto, M Angela.The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2000, 2(2): 76-83.
45.Stöcker, Walter, Grams, Frank, Reinemer, Peter, Bode, Wolfram, Baumann, Ulrich, Gomis‐Rüth, Franz‐Xaver and Mckay, David B. The metzincins—Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases. Protein Science, 1995, 4(5): 823-840.
46.Stetler-Stevenson, William G,Brown, Peter D,Onisto, Maurizio,Levy, Anna T and Liotta, Lance A. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem, 1990. 265(23): 13933-13938
47.Holmbeck, Kenn, Bianco, Paolo, Caterina, John, Yamada, Susan, Kromer, Mark, Kuznetsov, Sergei A, Mankani, Mahesh, Robey, Pamela Gehron, Poole, A Robin and Pidoux,Isabelle.
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell, 1999, 99(1): 81-92.
48.Klinge, U,Si, ZY,Zheng, H,Schumpelick, V,Bhardwaj, RS and Klosterhalfen, B. Collagen I/III and matrix metalloproteinases (MMP) 1 and 13 in the fascia of patients with incisional hernias. Journal of Investigative Surgery, 2001, 14(1): 47-54.
49.Ravanti, Laura,Heino, Jyrki,López-Otı́n, Carlos and Kähäri,
Veli-Matti. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. Journal of Biological Chemistry, 1999, 274(4): 2446-2455.
50.Zhang, Jinsong,Bai, Shan,Zhang, Xiaoming,Nagase, Hideaki and Sarras Jr, Michael P. The expression of gelatinase A (MMP-2) is required for normal development of zebrafish embryos. Development Genes and Evolution, 2003, 213(9): 456-463.
51.Orbe, Josune, Fernandez, L, Rábago, G, Belzunce, M, Monasterio, A, Roncal, C and Páramo, José A.Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003. 170(2): 269-276.
52.Gomez, DE, Alonso, DF, Yoshiji, Hand Thorgeirsson, UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. European Journal of Cell Biology, 1997, 74(2): 111-122.
53.Palanki, M.S.. Inhibitors of AP-1 and NF-kappa B mediated
transcriptional activation: therapeutic potential in autoimmune
diseases and structural diversity. Curr Med Chem, 2002. 9(2):
219-227.
54.Verma R P, Hansch C. Matrix metalloproteinases (MMPs): chemical–biological functions and (Q) SARs. Bioorganic & Medicinal Chemistry, 2007, 15(6): 2223-2268
55.Hanemaaijer, R,Koolwijk, Pieter,Le Clercq, L,De Vree, WJA and Van Hinsbergh, VWM. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochemical Journal, 1993, 296(3): 803-809.
56.Kondapaka S B, Fridman R, Reddy K B. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. International Journal of Cancer, 1997, 70(6): 722-726.
57.Han, Yuan-Ping, Tuan, Tai-Lan, Hughes, Michael, Wu, Huayang and Garner, Warren L. Transforming growth factor-β-and tumor necrosis factor-α-mediated induction and proteolytic activation of MMP-9 in human skin. Journal of Biological Chemistry, 2001, 276(25): 22341-22350.
58.Bowler P G. Wound pathophysiology, infection and therapeutic options. Annals of Medicine, 2002, 34(6): 419-427.
59.Chiodoni C, Colombo M P, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis[J]. Cancer and Metastasis Reviews, 2010, 29(2): 295-307.
60.Tak P P, Firestein G S. NF-κB: a key role in inflammatory diseases. The Journal of Clinical Investigation, 2001, 107(1): 7-11.
61.Huang, Suyun,Pettaway, Curtis A,Uehara, Hisanori,Bucana, Corazon
D and Fidler, Isaiah J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 2001, 20(31): 4188. 10p.
62.Aljada, Ahmad, Ghanim, Husam, Mohanty, Priya, Hofmeyer, Debbie, Tripathy, Devjit and Dandona, Paresh. Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). The Journal of Clinical Endocrinology & Metabolism, 2001, 86(12): 5988-5988.
63.Elshal M F, McCoy J P. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods, 2006, 38(4): 317-323.
64.Herlaar, E. and Z. Brown. p38 MAPK signalling cascades in inflammatory disease. Molecular Medicine Today, 1999. 5(10): 439-447.
65.Lee, Se-Jung,Park, Sung-Soo,Lee, Ung-Soo,Kim, Wun-Jae and Moon, Sung-Kwon. Signaling pathway for TNF-α induced MMP-9 expression: mediation through p38 MAP kinase,and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol,2008, 8: 1821−1826.
66.Wang, Xiaoying,Mori, Tatsuro,Jung, Jae-Chang,Fini, M Elizabethand Lo, Eng H .Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. Journal of Neurotrauma, 2002. 19(5): 615-625.
67.Werb Z. ECM and cell surface proteolysis: regulating cellular
ecology.Cell, 1997, 91(4): 439-442.
68.Page-McCaw A, Ewald A J, Werb Z. Matrix metalloproteinases and
the regulation of tissue remodelling. Nature Reviews Molecular
Cell Biology, 2007, 8(3): 221-233.
69.Tezvergil-Mutluay, Arzu,Agee, Kelli A,Hoshika, Tomohiro,Carrilho, Marcela,Breschi, Lorenzo,Tjäderhane, Leo,Nishitani, Yoshihiro,Carvalho, Ricardo M,Looney, Stephen and Tay, Franklin R. The requirement of zinc and calcium ions for functional MMP activity in demineralized dentin matrices. Dental Materials, 2010, 26(11): 1059-1067.
70.Matrisian L M. The matrix‐degrading metalloproteinases. Bioessays, 1992, 14(7): 455-463.
71.Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circulation Research, 2003, 92(8): 827-839.
72.Sypecka, Joanna,Dragun-Szymczak, Patrycja,Zalewska, Teresa and Domanska-Janik, Krystyna. Laminin promotes oligogliogenesis and increases MMPs activity in human neural stem cells of HUCB-NSC line. Acta Neurobiol Exp (Wars), 2009, 69(1): 37-45.
73.Nagase, H.. Activation mechanisms of matrix metalloproteinases.
Biol Chem, 1997. 378(3-4): 151-160.
74.Chapman, H.A.. Plasminogen activators, integrins, and the
coordinated regulation of cell adhesion and migration. Curr Opin
Cell Biol, 1997. 9(5): 714-724.
75.Malemud, C.J.. Matrix metalloproteinases (MMPs) in health and disease: an overview. Frontiers in bioscience: A Journal and Virtual Library, 2005. 11: 1696-1701.
76.Brew, K., D. Dinakarpandian, and H. Nagase. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology, 2000. 1477(1): 267-283.
77.Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 2006, 69(3): 562-573.
78.Cuzner M L, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. Journal of Neuroimmunology, 1999, 94(1): 1-14.
79.Heymans, Stephane,Luttun, Aernout,Nuyens, Dieter,Theilmeier, G,Creemers, E,Moons, Lieve,Dyspersin, GD,Cleutjens, JPM,Shipley, M and Angellilo, A. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine, 1999, 5(10): 1135-1142.
80.Gali-Muhtasib, H., A. Roessner, and R.Schneider-Stock.
Thymoquinone: a promising anti-cancer drug from natural sources. The International Journal of Biochemistry & Cell Biology, 2006. 38(8): 1249-1253.
81.Shoieb, Ahmed M,Elgayyar, Mona,Dudrick, Paul S,Bell, John L and Tithof, Patricia K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. International Journal of Oncology, 2003, 22(1): 107-113.
82.Gali-Muhtasib, Hala U,Kheir, Wassim G Abou,Kheir, Lynn A,Darwiche, Nadine and Crooks, Peter A. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anti-Cancer Drugs, 2004, 15(4): 389-399.
83.De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer, 2013, 13(2): 97-110.
84.Liotta, LA,Tryggvason, K,Garbisa, S,Hart, Ian,Foltz, CM and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 1980, 284(5751): 67-68.
85.Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991, 64(2): 327-336.
86.Chu, Shu‐Chen,Chiou, Hui‐Ling,Chen, Pei‐Ni,Yang, Shun‐Fa and Hsieh, Yih‐Shou. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase‐plasminogen activator and matrix metalloproteinase‐2. Molecular Carcinogenesis, 2004, 40(3): 143-149.
87.Stack M S, Ellerbroek S M, Fishman D A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. International Journal of Oncology, 1998, 12(3): 569-645.
88.Roomi, MW, Monterrey, JC, Kalinovsky, T, Rath, M and Niedzwiecki, A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncology Reports, 2009, 21(5): 1323-1333.
89.Cavallaro, U. and G. Christofori. Cell adhesion in tumor invasion
and metastasis: loss of the glue is not enough. Biochim Biophys
Acta, 2001. 1552(1): 39-45.
90.Chen, Rong-Xin,Xia, Yun-Hong,Xue, Tong-Chun,Zhang, Hong and Ye, Sheng-Long. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncology Reports, 2011, 25(3): 803-808.
91.Shia, Chi-Sheng,Suresh, Govindan,Hou, Yu-Chi,Lin, Yu-Chin,Chao, Pei-Dawn Lee and Juang, Shin-Hun. Suppression on metastasis by rhubarb through modulation on MMP-2 and uPA in human A549 lung adenocarcinoma: an ex vivo approach. Journal of Ethnopharmacology, 2011, 133(2): 426-433.
92.Chen, Pei-Ni, Hsieh, Yih-Shou, Chiou, Hui-Ling and Chu, Shu-Chen. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chemico-Biological Interactions, 2005, 156(2): 141-150.
93.Lin, Kuei-Li,Chien, Ching-Ming,Hsieh, Chi-Ying,Tsai, Pei-Chien,Chang, Long-Sen and Lin, Shinne-Ren
. Antimetastatic potential of cardiotoxin III involves inactivation of PI3K/Akt and p38 MAPK signaling pathways in human breast cancer MDA-MB-231 cells. Life Sciences, 2012, 90(1): 54-65.
94.Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Research, 2009, 19(2): 156-172.
|